Julie Nonnekens

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 17

Top Venues

Cancers

European journal of nuclear medicine and molecular imaging

EJNMMI physics

Prostate cancer and prostatic diseases

Erasmus MC

Université Paul Sabatier (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Erasmus MC Apr 01 2018

Netherlands

Assistant Professor and Principal Investigator :: Molecular Genetics and Radiology & Nuclear Medicine

Erasmus MC Mar 01 2014 - Mar 31 2018

Netherlands

Postdoctoral fellow :: Molecular Genetics and Radiology & Nuclear Medicine

Hubrecht Institute Jul 01 2013 - Feb 28 2014

Netherlands

Postdoctoral fellow

CNRS Délégation Midi-Pyrénées Oct 01 2009 - Jul 01 2013

France

PhD student

Education History

Université Paul Sabatier Oct 01 2009 - Jun 17 2013

France

PHD :: Institute IPBS

Wageningen University Sep 01 2004 - Aug 31 2009

Netherlands

MSC

Publications

Thom G A Reuvers, Vivian Grandia, Renata M C Brandt, Majd Arab, Sybren L N Maas, Eelke M Bos, Julie Nonnekens
Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids. Cancers 16 (14) (2024)
Thom G A Reuvers, Vivian Grandia, Renata M C Brandt, Majd Arab, Sybren L N Maas, Eelke M Bos, Julie Nonnekens
Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids. Cancers 16 (14) (2024)
Thom G A Reuvers, Vivian Grandia, Renata M C Brandt, Majd Arab, Sybren L N Maas, Eelke M Bos, Julie Nonnekens
Investigating the Radiobiological Response to Peptide Receptor Radionuclide Therapy Using Patient-Derived Meningioma Spheroids. Cancers 16 (14) (2024)
Danny Feijtel, Thom G A Reuvers, Christine van Tuyll-van Serooskerken, Corrina M A de Ridder, Debra C Stuurman, Erik de Blois, Nicole S Verkaik, Peter de Bruijn, Stijn L W Koolen, Marion de Jong, Julie Nonnekens
In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. Cancers 15 (3) (2023)
Danny Feijtel, Thom G A Reuvers, Christine van Tuyll-van Serooskerken, Corrina M A de Ridder, Debra C Stuurman, Erik de Blois, Nicole S Verkaik, Peter de Bruijn, Stijn L W Koolen, Marion de Jong, Julie Nonnekens
In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. Cancers 15 (3) (2023)
Eline A M Ruigrok, Giulia Tamborino, Erik de Blois, Stefan J Roobol, Nicole Verkaik, Marijke De Saint-Hubert, Mark W Konijnenberg, Wytske M van Weerden, Marion de Jong, Julie Nonnekens
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. European journal of nuclear medicine and molecular imaging 49 (11) (2022)
Morticia N Becx, Noémie S Minczeles, Tessa Brabander, Wouter W de Herder, Julie Nonnekens, Johannes Hofland
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE in Neuroendocrine Tumor Patients. Cancers 14 (23) (2022)
Morticia N Becx, Noémie S Minczeles, Tessa Brabander, Wouter W de Herder, Julie Nonnekens, Johannes Hofland
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE in Neuroendocrine Tumor Patients. Cancers 14 (23) (2022)
Morticia N Becx, Noémie S Minczeles, Tessa Brabander, Wouter W de Herder, Julie Nonnekens, Johannes Hofland
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE in Neuroendocrine Tumor Patients. Cancers 14 (23) (2022)
Eline A M Ruigrok, Nicole S Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J Roobol, Dik C van Gent, Marion de Jong, Thomas A Kirkland, Julie Nonnekens
Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment. International journal of molecular sciences 23 (14) (2022)
Sofia Koustoulidou, Maryana Handula, Corrina de Ridder, Debra Stuurman, Savanne Beekman, Marion de Jong, Julie Nonnekens, Yann Seimbille
Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors. Pharmaceuticals (Basel, Switzerland) 15 (9) (2022)
Eline A M Ruigrok, Nicole van Vliet, Simone U Dalm, Erik de Blois, Dik C van Gent, Joost Haeck, Corrina de Ridder, Debra Stuurman, Mark W Konijnenberg, Wytske M van Weerden, Marion de Jong, Julie Nonnekens
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. European journal of nuclear medicine and molecular imaging 48 (5) (2020)
Giulia Tamborino, Marijke De Saint-Hubert, Lara Struelens, Dayana C Seoane, Eline A M Ruigrok, An Aerts, Wiggert A van Cappellen, Marion de Jong, Mark W Konijnenberg, Julie Nonnekens
Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity. EJNMMI physics 7 (1) (2020)
Julie Nonnekens, Margret Schottelius
"Luke! Luke! Don't! It's a trap!"-spotlight on bias in animal experiments in nuclear oncology. European journal of nuclear medicine and molecular imaging 47 (5) (2020)
Thom G A Reuvers, Roland Kanaar, Julie Nonnekens
DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. Cancers 12 (8) (2020)
Wenhao Zhang, Dik C van Gent, Luca Incrocci, Wytske M van Weerden, Julie Nonnekens
Role of the DNA damage response in prostate cancer formation, progression and treatment. Prostate cancer and prostatic diseases 23 (1) (2019)
Wenhao Zhang, Wytske M van Weerden, Corrina M A de Ridder, Sigrun Erkens-Schulze, Edgar Schönfeld, Titia G Meijer, Roland Kanaar, Dik C van Gent, Julie Nonnekens
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response. The Prostate 79 (4) (2018)

Julie Nonnekens.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Julie Nonnekens